Blog

Jul 22, 2023

Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary. This reports provides a data-driven overview of the current and future competitive landscape in JMD therapeutics. - More than 555,110 diagnosed prevalent cases of JMD are anticipated in 2023

Summary. This reports provides a data-driven overview of the current and future competitive landscape in JMD therapeutics. - More than 555,110 diagnosed prevalent cases of JMD are anticipated in 2023 in the 16 countries covered in epidemiology forecast for JMD.

New York, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Juvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06487053/?utm_source=GNW SummaryThis reports provides a data-driven overview of the current and future competitive landscape in JMD therapeutics.- More than 555,110 diagnosed prevalent cases of JMD are anticipated in 2023 in the 16 countries covered in epidemiology forecast for JMD.- There are significant unmet clinical need in the JMD treatment space due to a lack of marketed therapies.- R&D activity in the JMD space is very limited, with only six pipeline drugs in the mid-to-late-stage of development.- Clinical trial activity in JMD has been very limited during the past 10 years, with only 26 trials conducted overall.ScopeJuvenile Macular Degeneration (JMD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include -- Disease Landscape- Disease Overview- Epidemiology Overview- Treatment Overview- Marketed Products Assessment- Breakdown by Mechanism of Action, Route of Administration- Product Profiles with Sales Forecast- Pricing and Reimbursement Assessment- Annual Therapy Cost- Time to Pricing and Time to Reimbursement- Pipeline Assessment- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration- Product Profiles with Sales Forecast- Late-to-mid-stage Pipeline Drugs- Phase Transition Success Rate and Likelihood of Approval- Clinical Trials Assessment- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status- Enrolment Analytics, Site Analytics, Feasibility Analysis- Deals Landscape- Mergers, Acquisitions, and Strategic Alliances by Region- Overview of Recent Deals- Commercial Assessment- Key Market Players- Future Market CatalystsReasons to Buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the JMD market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global JMD market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.Read the full report: https://www.reportlinker.com/p06487053/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________